New drug trialled in Sheffield offers hope to children with rare and severe epilepsy

A new drug trialled in Sheffield has dramatically reduced seizures in children with a rare and severe form of epilepsy, giving families hope for the first time.

Early trial results show the treatment, called zorevunersen, slashed seizures in youngsters with Dravet syndrome - a genetic condition that often begins in the first year of life and is notoriously difficult to treat.

Experts say the drug could also help ease the learning and behavioural difficulties linked to the disorder.

Early trial results show the treatment, called zorevunersen, slashed seizures in youngsters with Dravet syndrome - a genetic condition that often begins in the first year of life and is notoriously difficult to treat.placeholder image
Early trial results show the treatment, called zorevunersen, slashed seizures in youngsters with Dravet syndrome - a genetic condition that often begins in the first year of life and is notoriously difficult to treat. | Adobe

One mother from Yorkshire, whose son took part in the trial, said the treatment has “completely changed” their lives.

Dravet syndrome affects around one in 15,000 births in the UK and usually develops into treatment-resistant epilepsy.

Children with the condition often also struggle with speech and feeding, as well as intellectual disabilities and developmental delays.

The trial, led by University College London (UCL) and Great Ormond Street Hospital (Gosh), involved 81 children aged between two and 18 with Dravet syndrome in the UK and the US.

Some 19 children in the trial were patients at UK hospitals, including Gosh, Sheffield Children's Hospital , Evelina London Children's Hospital and The Royal Hospital for Children in Glasgow .

Freddie Truelove , eight, from Huddersfield , started taking zorevunersen in 2021.

He used to have more than a dozen seizures a night and now has one or two, lasting just seconds, every three to five days.

His mother, Lauren Truelove , said: "The trial has completely changed our lives.

"We now have a life we didn't ever think was possible and most importantly, it's a life that Freddie can enjoy."

Researchers found that youngsters who were given 70mg of zorevunersenin in the first part of the trial - either in one, two or three doses - saw a reduction in seizures of between 59% and 91% over the first 20 months of the extension studies.

Lead author Helen Cross , director and professor of childhood epilepsy at the UCL Institute of Child Health , and an honorary consultant in paediatric neurology at Gosh, said:

"I regularly see patients with hard-to-treat genetic epilepsies with impacts that go beyond seizures and it's heartbreaking when treatment options are limited.

"This new treatment could help children with Dravet syndrome lead much healthier and happier lives."

Researchers said the findings, published in the New England Journal of Medicine , "support the continued development of zorevunersen as a potential disease-modifying treatment for Dravet syndrome".

The trial also found that "most adverse events were mild or moderate", with the most common being post-lumbar puncture syndrome, which can cause headaches.

Prof Cross added: "Overall, our findings showed that zorevunersen is safe to use and well tolerated by most patients and supports further evaluation in the ongoing phase three study."

News you can trust since 1887
Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice